Efficacy of fetal stem cells in Duchenne muscular dystrophy therapy
Author(s) -
Nataliia Sych,
Mariya Klunnik,
Olena Ivankova,
Irina Matyaschuk,
Mariya Demchuk,
A. V. Nоvytska,
Inna Arkhipenko,
Iuliia Shalita,
Dario Siniscalco
Publication year - 2014
Publication title -
journal of neurorestoratology
Language(s) - English
Resource type - Journals
ISSN - 2324-2426
DOI - 10.2147/jn.s57276
Subject(s) - duchenne muscular dystrophy , medicine , stem cell therapy , ejection fraction , stem cell , cell therapy , creatine kinase , enzyme replacement therapy , muscular dystrophy , cardiology , dystrophin , heart failure , oncology , disease , transplantation , biology , genetics
The absence of effective treatment methods for Duchenne muscular dystrophy (DMD) calls for new therapeutic approaches. One of the promising treatment methods for DMD is stem cell therapy. This study demonstrates the impact of fetal stem cells (FSCs) on functional capacity and life quality of DMD patients and the ability of FSCs to prevent DMD-related complica- tions in order to inhibit the disease progression. FSC therapy substantially improves functional capacity, life quality, left ventricular ejection fraction, and forced vital capacity of the lungs of DMD patients; this was confirmed by comparison of neurological, laboratory (aspartate amino- transferase, alanine aminotransferase, creatine phosphokinase, and lactate dehydrogenase), and morphofunctional findings (left ventricular ejection fraction and forced vital capacity) in DMD patients before the treatment, and 6 and 12 months after the FSC treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom